home / stock / inzy / inzy news

INZY News and Press, Inozyme Pharma Inc. From 07/19/23

Stock Information
Company Name: Inozyme Pharma Inc.
Stock Symbol: INZY
Market: NASDAQ
Website: inozyme.com
Menu
INZY INZY Quote INZY Short INZY News INZY Articles INZY Message Board
Get INZY Alerts

News, Short Squeeze, Breakout and More Instantly...
INZY - Inozyme Pharma to Provide ENPP1 Deficiency Program Update on July 26, 2023

– Conference call and webcast to be held on July 26, 2023, at 8am ET – BOSTON, July 19, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developi...
INZY - Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in a Phase 1b Trial of INZ-701

BOSTON, June 27, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced dosing of the first patient in its ENE...

INZY - Inozyme Pharma to Present at the Jefferies Healthcare Conference

BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Douglas A. Treco, Ph.D., the company&#...

INZY - CG, AVPT and CBRL are among after hour movers

2023-05-15 17:42:50 ET Gainers: Dragonfly Energy Holdings  ( DFLI ) +11% . The Carlyle Group  ( CG ) +8% . Cara Therapeutics ( CARA ) +6% . OmniAb ( OABI ) +6% . Inozyme Pharma ( INZY ) +6% . Losers: Coherus Bio...
INZY - Inozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business Highlights

- Upcoming clinical and regulatory milestones remain on track with previous guidance – - Current cash, cash equivalents and short-term investments anticipated to fund cash flow requirements into the fourth quarter of 2024 - BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Inozyme...

INZY - Inozyme: Early Rare Disease Data, Decent Cash, No Major Near-Term Catalysts

2023-05-09 01:45:09 ET Summary Inozyme targets rare diseases characterised by pyrophosphate deficiency. It has produced some early positive data. Lead asset INZ-701 may start a pivotal trial this year. Inozyme ( INZY ) is a clinical stage developer of rare disease th...

INZY - Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, May 03, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc . (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that the Company granted stock options...
INZY - Inozyme Pharma to Present Recently Announced Preliminary Data from Ongoing Phase 1/2 Trial in ENPP1 Deficiency at the European Calcified Tissue Society Congress (ECTS)

BOSTON, April 14, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Yves Sabbagh, Ph.D., the company ...

INZY - Inozyme Pharma to Participate at the 22nd Annual Needham Virtual Healthcare Conference

BOSTON, April 11, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical- stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Douglas A. Treco, Ph.D., the company...

INZY - HRTX, NNVC and CDLX among mid-day movers

2023-04-06 13:25:31 ET Gainers: Guardforce AI ( GFAI ) +61% . Amesite ( AMST ) +31% . Tellurian ( TELL ) +29% . The Singing Machine Company ( MICS ) +27% . Cardlytics ( CDLX ) +22% . Finance Of America Companies ( FOA ) ...
Previous 10 Next 10